1870 related articles for article (PubMed ID: 25659285)
1. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
2. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Sulkowski MS; Naggie S; Lalezari J; Fessel WJ; Mounzer K; Shuhart M; Luetkemeyer AF; Asmuth D; Gaggar A; Ni L; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Rodriguez-Torres M; Dieterich D;
JAMA; 2014 Jul 23-30; 312(4):353-61. PubMed ID: 25038354
[TBL] [Abstract][Full Text] [Related]
7. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
Zeuzem S; Dusheiko GM; Salupere R; Mangia A; Flisiak R; Hyland RH; Illeperuma A; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Weiland O; Reesink HW; Ferenci P; Hézode C; Esteban R;
N Engl J Med; 2014 May; 370(21):1993-2001. PubMed ID: 24795201
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
Jacobson IM; Gordon SC; Kowdley KV; Yoshida EM; Rodriguez-Torres M; Sulkowski MS; Shiffman ML; Lawitz E; Everson G; Bennett M; Schiff E; Al-Assi MT; Subramanian GM; An D; Lin M; McNally J; Brainard D; Symonds WT; McHutchison JG; Patel K; Feld J; Pianko S; Nelson DR; ;
N Engl J Med; 2013 May; 368(20):1867-77. PubMed ID: 23607593
[TBL] [Abstract][Full Text] [Related]
12. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir for previously untreated chronic hepatitis C infection.
Lawitz E; Mangia A; Wyles D; Rodriguez-Torres M; Hassanein T; Gordon SC; Schultz M; Davis MN; Kayali Z; Reddy KR; Jacobson IM; Kowdley KV; Nyberg L; Subramanian GM; Hyland RH; Arterburn S; Jiang D; McNally J; Brainard D; Symonds WT; McHutchison JG; Sheikh AM; Younossi Z; Gane EJ
N Engl J Med; 2013 May; 368(20):1878-87. PubMed ID: 23607594
[TBL] [Abstract][Full Text] [Related]
15. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
[TBL] [Abstract][Full Text] [Related]
16. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
